EVI1 is expressed in megakaryocyte cell lineage and enforced expression of EVI1 in UT-7/GM cells induces megakaryocyte differentiation

Biochemical and Biophysical Research Communications
Seiichi ShimizuKazuhiro Morishita

Abstract

3q21q26 syndrome, an acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with chromosomal translocations or inversions between the bands 3q21 and 3q26, is frequently associated with dysmegakaryocytopoiesis and increased platelet counts at the initial diagnosis. Since the EVI1 gene at 3q26 is transcriptionally activated in 3q21q26 syndrome, we assessed the role of EVI1 gene expression in the abnormal megakaryocytic differentiation in 3q21q26 syndrome. RT-PCR analysis of various types of hematopoietic cells revealed that the EVI1 gene is expressed specifically in CD34(+) cells, megakaryocytes, and platelets. UT-7 is a human immature megakaryoblastic leukemia cell line with dependence for the growth on granulocyte-macrophage colony-stimulating factor (GM-CSF) (designated at UT-7/GM) and with a differentiation capacity to erythroid (UT-7/EPO) and megakaryocytic lineages (UT-7/TPO) by erythropoietin (EPO) and thrombopoietin (TPO), respectively. Among three UT-7 sublines, UT-7/GM, UT-7/EPO, and UT-7/TPO, expression of the EVI1 gene was detected at low levels in UT-7/GM and UT-7/EPO cells, but was detected at a higher level in UT-7/TPO cells. When UT-7/GM cells were cultured with TPO, the level of EVI1 expression was increa...Continue Reading

References

May 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·K MorishitaJ N Ihle
Apr 26, 1994·Proceedings of the National Academy of Sciences of the United States of America·G NuciforaJ D Rowley
Jul 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·B L KreiderJ N Ihle
Jan 1, 1993·Molecular and Cellular Biology·V LemarchandelP H Roméo

❮ Previous
Next ❯

Citations

Apr 2, 2010·Leukemia·B V BalgobindM M van den Heuvel-Eibrink
Jan 19, 2012·Molecular Therapy : the Journal of the American Society of Gene Therapy·Luca BiascoAlessandro Aiuti
Oct 27, 2015·International Journal of Oncology·Xiaofen YuanGuosheng Jiang
Nov 19, 2014·PloS One·Nathalie Delesque-TouchardFrançoise Bono
Apr 18, 2015·Journal of Hematology & Oncology·Gerwin HellerRotraud Wieser
Apr 8, 2015·Nature Communications·William TapperNicholas C P Cross
Jan 15, 2013·Journal of Thrombosis and Haemostasis : JTH·M R Tijssen, C Ghevaert
Mar 24, 2021·Blood Cancer Journal·Christine BirdwellKapil N Bhalla

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.